Jake Morgan

Assistant Professor

Boston University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Jake Morgan is an Assistant Professor at Boston University, specializing in public health and opioid overdose prevention. His recent research focuses on naloxone distribution patterns, health equity, and intervention strategies to improve access to life-saving medications among at-risk populations in the United States. Dr. Morgan's work encompasses geospatial analysis, simulation modeling, and health communication interventions, contributing significantly to the understanding of opioid use disorder in diverse communities.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Sean M. Murphy

Associate Professor of Research

Weill Cornell Medical College

UNITED STATES

View details

Avik Chatterjee

UNITED STATES

View details

Brandon D. L. Marshall

UNITED STATES

View details

Bruce Schackman

Saul P. Steinberg Distinguished Professor and Executive Vice Chair

Weill Cornell Medicine

UNITED STATES

View details

Sabrina A. Assoumou

Boston University School of Medicine

UNITED STATES

View details

Czarina Behrends

Assistant Professor

Weill Cornell Medical College

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jake Morgan

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

A geospatial analysis of naloxone distribution patterns in the Massachusetts overdose education and naloxone distribution program (MA OEND)

You have to be alive to enjoy the porridge: The role of Goldilocks naloxone dosing in a world of hungry bears

Improving racial/ethnic health equity and naloxone access among people at risk for opioid overdose: A simulation modeling analysis of community‐based naloxone distribution strategies in Massachusetts, United States

Testing a persuasive health communication intervention (PHCI) for emergency department patients who declined rapid HIV/HCV screening: a randomised controlled trial study protocol

Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals

Comparison of a national commercial pharmacy naloxone data source to state and city pharmacy naloxone data sources—Rhode Island, Massachusetts, and New York City, 2013–2019

Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID‐19 pandemic: An interrupted time‐series analysis in Massachusetts, USA

The limits of innovation: Directly addressing known challenges is necessary to improve the real‐world experience of novel medications for opioid use disorder

Commentary on Karnik et al.: Harmonization now—the need for consistent, validated measures to identify opioid use disorder in observational data

Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis

The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City

Determining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set

Community‐based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island

Opioid use disorder and overdose among youth following an initial opioid prescription

Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort

HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients

Collaborators (6)

Sean M. Murphy

Avik Chatterjee

Brandon D. L. Marshall

Bruce Schackman

Sabrina A. Assoumou

Czarina Behrends

Make your next move.